Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q2 2024 Earnings Conference
Earnings Call Summary | Supernus Pharmaceuticals(SUPN.US) Q2 2024 Earnings Conference
The following is a summary of the Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript:
以下是Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 业绩会议要点摘要:
Financial Performance:
金融业绩:
Supernus Pharmaceuticals reported Q2 2024 total revenue of $168.3 million, up from $135.5 million in Q2 2023.
Qelbree showed significant growth with a 92% increase in net sales totaling $59 million for Q2 2024.
GOCOVRI net sales increased by 10% year-over-year to $32 million in Q2 2024.
Net earnings for Q2 2024 were $19.9 million, or $0.36 per diluted share, compared to a net loss of $831,000 in Q2 2023.
Supernus Pharmaceuticals报告Q2 2024年总营业收入为16830万美元,较Q2 2023年的13550万美元增长。
Qelbree实现了92%的增长,Q2 2024年净销售额达到5900万美元。
GOCOVRI净销售额在2024年Q2同比增长了10%,为3200万美元。
2024年Q2净收益为1990万美元,每股摊薄收益为0.36美元,而2023年Q2净亏损为83.1万美元。
Business Progress:
业务进展:
Supernus expanded its product pipeline with SPN-817 for treatment-resistant seizures and SPN-820 for depression.
Anticipate commencement of Phase 2b study with SPN-817 by end of 2024 and results from Phase 2b study of SPN-820 in H1 2025.
Activities to strengthen market positioning include strategic corporate development initiatives targeting growth opportunities.
Supernus扩大其产品线,推出SPN-817用于治疗难治性癫痫和SPN-820用于治疗抑郁症。
预计SPN-817的第二阶段研究将在2024年底开始,并于2025年上半年公布SPN-820的第二阶段研究结果。
加强市场定位的活动包括有针对性的措施,以引领公司发展机遇。
Opportunities:
机会:
The company expects continued growth driven by key products like Qelbree and GOCOVRI.
公司预计Qelbree和GOCOVRI等主要产品将继续推动业绩增长。
Risks:
风险:
Anticipated entry of a generic competitor for Oxtellar XR later in 2024 poses a risk to sales projections.
预计2024年后期将有一家仿制竞争对手进入Oxtellar XR市场,这对销售预测构成了风险。
More details: Supernus Pharmaceuticals IR
更多详情:Supernus Pharmaceuticals IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息,请参阅IR网站。本文只是为投资者提供参考,没有任何指导或推荐建议。